Bristol Myers Squibb stock holds near USD 62.68 as growth widens

Published on 09/23/2026 at 04:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock traded at USD 62.68 on September 22, 2026, below its USD 68.64 yearly high. Q2 revenue rose 6 percent to USD 12.97 billion.

BMY, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb Company (ISIN US1101221083) traded at USD 62.68 on the NYSE on September 22, 2026, up USD 0.06 during the session. The price remained USD 5.96 below the 52-week high of USD 68.64, while the latest market capitalization stood at USD 128.04 billion.

Growth portfolio leads results

The latest reported quarter was Q2 2026. According to Stock Titan, revenue reached USD 12.973 billion, up 6 percent year over year, while net earnings attributable to BMS rose to USD 3.317 billion. Non-GAAP EPS increased to USD 2.04 from USD 1.46 in Q2 2025, a gain of USD 0.58.

The composition of sales matters more than the headline growth rate. Q2 2026 Growth Portfolio revenue reached USD 7.560 billion, up 15 percent, whereas the Legacy Portfolio declined 4 percent to USD 5.422 billion. Eliquis revenue rose 22 percent to USD 4.481 billion, but generic pressure reduced sales of Revlimid and Pomalyst or Imnovid.

Analyst target stays above price

MarketBeat reported on September 22, 2026, that analysts had a Moderate Buy consensus and an average price target of USD 66.72. The average target stood USD 4.04 above the September 22 price, while Guggenheim raised its target from USD 72.00 to USD 75.00 on July 31, 2026, and Royal Bank of Canada increased its target from USD 60.00 to USD 64.00 on the same date.

The valuation and balance sheet provide a counterweight to the product mix. MarketBeat reported a price-to-earnings ratio of 13.80, a debt-to-equity ratio of 1.89 and a 200-day moving average of USD 60.13 on September 22, 2026. For the first half of 2026, operating cash flow was USD 4.497 billion, down from USD 5.871 billion in the first half of 2025, while long-term debt stood at USD 42.093 billion on June 30, 2026.

Stock remains below yearly high

Bristol Myers Squibb stock closed at USD 62.68 on the NYSE on September 22, 2026, with reported volume of 2,184,600 shares. The 52-week range was USD 42.52 to USD 68.64, placing the price USD 20.16 above the low and USD 5.96 below the high.